{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:53:47Z","timestamp":1740142427575,"version":"3.37.3"},"reference-count":16,"publisher":"FapUNIFESP (SciELO)","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"abstract":"<jats:p>ABSTRACT Patients on anticoagulant or antiplatelet therapy are often required to discontinue these medications before and during surgical or invasive procedures. In some cases, the patient stops the treatment without medical supervision. These situations may increase stroke risk.  Objective  To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil.  Methods  Cross-sectional, retrospective and descriptive study of stroke inpatients for three years. Medical reports were reviewed to find study participants, stroke characteristics, risk factors, reasons and time of drug interruption.  Results  In three years, there were 360 stroke and TIA inpatients, of whom 27 (7.5%) had a history of antiplatelet or vitamin K antagonist interruption correlated with the time of the event (81% ischemic stroke, 19% TIA). The median time between antiplatelet interruption and an ischemic event was five days, and 62% of events occurred within seven days after drug suspension. For vitamin K antagonists, the average time to the ischemic event was 10.4 days (SD = 5.7), and in 67% of patients, the time between drug discontinuation and the event was 7-14 days. The most frequent reason for drug suspension was patient negligence (37%), followed by planned surgery or invasive examination (26%) and side effects, including hemorrhage (18.5%).  Conclusion  Antiplatelet or vitamin K antagonist suspension has a temporal relationship with the occurrence of stroke and TIA. Since these events are preventable, it is crucial that healthcare professionals convince their patients that drug withdrawal can cause serious consequences.<\/jats:p>","DOI":"10.1590\/0004-282x20190066","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T15:24:56Z","timestamp":1564241096000},"page":"456-459","source":"Crossref","is-referenced-by-count":3,"title":["Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption"],"prefix":"10.1590","volume":"77","author":[{"given":"Vanessa","family":"RIZELIO","sequence":"first","affiliation":[{"name":"nstituto de Neurologia de Curitiba,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Luiz Borba","family":"MACUCO","sequence":"additional","affiliation":[{"name":"nstituto de Neurologia de Curitiba,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Koiti","family":"SATO","sequence":"additional","affiliation":[{"name":"nstituto de Neurologia de Curitiba,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Tereza de Moraes Souza","family":"NASCIMENTO","sequence":"additional","affiliation":[{"name":"nstituto de Neurologia de Curitiba,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Krause Martinez de","family":"SOUZA","sequence":"additional","affiliation":[{"name":"nstituto de Neurologia de Curitiba,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-7475","authenticated-orcid":false,"given":"Pedro Andr\u00e9","family":"KOWACS","sequence":"additional","affiliation":[{"name":"nstituto de Neurologia de Curitiba,  Brasil; Universidade Federal do Paran\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2019,7]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/archinte.164.12.1319","article-title":"Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen","volume":"164","author":"Douketis JD","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archneur.62.8.1217","article-title":"Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke","volume":"62","author":"Maulaz AB","year":"2005","journal-title":"Arch Neurol"},{"issue":"jul19 1","key":"ref3","doi-asserted-by":"crossref","first-page":"d4094","DOI":"10.1136\/bmj.d4094","article-title":"Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care","volume":"343","author":"Rodr\u00edguez LA","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1212\/WNL.0b013e31820d62b5","article-title":"Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study","volume":"76","author":"Garc\u00eda Rodr\u00edguez LA","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-005-0858-0","article-title":"Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke","volume":"252","author":"Schryver EL","year":"2005","journal-title":"J Neurol"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.01.006","article-title":"Withdrawal of antithrombotic agents and the risk of stroke","volume":"25","author":"Wagner ML","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"22","key":"ref7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1212\/WNL.0b013e318294b32d","article-title":"Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"80","author":"Armstrong MJ","year":"2013","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/anae.12900","article-title":"Management of peri-operative anti-thrombotic therapy","volume":"70","author":"Veen JJ","year":"2015","journal-title":"Anaesthesia"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis JD","year":"2012","journal-title":"Chest"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.04.006","article-title":"Perioperative Heparin bridging in atrial fibrillation patients requiring temporary interruption of anticoagulation: evidence from meta-analysis","volume":"25","author":"Ayoub K","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00392-011-0310-7","article-title":"Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation","volume":"100","author":"Diehl P","year":"2011","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.0306-5251.2001.01453.x","article-title":"Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers","volume":"52","author":"Weber AA","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000365732","article-title":"Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death: a cohort study","volume":"43","author":"Ostergaard K","year":"2014","journal-title":"Neuroepidemiology"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/eurheartj\/12.11.1225","article-title":"Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients","volume":"12","author":"Grip L","year":"1991","journal-title":"Eur Heart J"},{"issue":"5-6","key":"ref15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000446406","article-title":"Risk of ischemic stroke in high risk atrial fibrillation patients during periods of warfarin discontinuation for surgical procedures","volume":"42","author":"Qureshi AI","year":"2016","journal-title":"Cerebrovasc Dis"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1185\/03007995.2015.1082995","article-title":"Stroke associated with discontinuation of warfarin therapy for atrial fibrillation","volume":"31","author":"Spivey CA","year":"2015","journal-title":"Curr Med Res Opin"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v77n7\/0004-282X-anp-77-7-0456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T16:43:51Z","timestamp":1581439431000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2019000700456&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["S0004-282X2019000700456"],"URL":"https:\/\/doi.org\/10.1590\/0004-282x20190066","relation":{},"ISSN":["1678-4227","0004-282X"],"issn-type":[{"type":"electronic","value":"1678-4227"},{"type":"print","value":"0004-282X"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}